News Blog

We are exited to join the annual Symposium of the TRR305 "Striking a moving target: From mechanisms of metastatic organ colonisation to novel systemic therapies".

We are looking for a highly motivated team member to join our young and open-minded research group. If you are enthusiastic about supporting the translation of preclinical findings into personalized medicine, we look forward to receiving your detailed application.

Today Lydia started as a W2 professor at the Friedrich-Alexander University in Erlangen at the Chair of Experimental Medicine 1.

Tabea will present her work about deciphering the molecular mechanism of LIN28B in tumor induction, maintenance and metastastic spread in squamouc cell lung cancer. Visit her poster P16!

We are happy to get the opportunity to present our work at the MSNZ Symposium. Lydia will give a talk about therapeutic targeting of small-cell lung cancer metastasis.

Today our homepage of the Center for Molecular Medicine Cologne was lunched.

We are happy to announce that the annual retreat of the Clinic I of Internal Medicine will take place in person. Lydia will chair the session Solid Tumors and moderate the Workshop Reinforcement of the scientific network and personal support.

The IPMM (Interdisciplinary Program Molecular Medicine) days will take place luckily in person and Tabea will present her poster with the title Deciphering the Molecular Mechanisms of LIN28B in Tumor Induction, Tumor Maintenance and Metastatic tracks in squamous cell lung cancer.

Charlotte presented her poster with the title Angiopoietin-2/ITGB1 targeted therapy suppresses tumor cell invasion and the formation of metastasis in small cell lung cancer at the Study Advisory Board MSSO Meeting which took place in the Center for Molecular Medicine Cologne.

Today Tabea has her first day in the lab. She will investigate novel therapeutic strategies for squamous cell lung carcinomas (SQLC). LIN28B expression marks a clinically relevant subgroup of patients which may benefit from anti-angiogenic therapy and immune checkpoint blockade. Welcome Tabea!